CTD Dossier Preparation K. Srikantha Reddy Sr

Slides:



Advertisements
Similar presentations
1 Future strategy for e-submission as seen by industry Dr Michael Colmorgen, IFAH-Europe 2nd Veterinary Workshop on E-submission 4 Dec 2009, EMEA, London.
Advertisements

1 Harmonisation of requirements: where we are Erik Waterdrinker, IFAH-Europe 2nd Veterinary Workshop on E-submission 4 Dec 2009, EMEA, London.
New Services for Data Creators and Providers Louise Corti, Head ESDS Qualidata/ Outreach & Training Alasdair Crockett, ESDS Data Services Manager.
Dr. Raghuveer Pharma Consultants D R P C Quality. Perfection. Confidentiality. D R P C Quality. Perfection. Confidentiality. 1.
PLANNING AND IMPLEMENTING AN eAppeal: THE BRITISH COLUMBIA EXPERIENCE Tim Outerbridge, Law Officer, BC Court of Appeal Andrew Clark, Consultant.
Electronic Theses and Dissertations: Benefits, Issues, and the University of Waterloo Approach
GMP Document and Record Retention
The Application for Renewal Accreditation: Electronic Submissions.
eCTD – A TOOL to QUICK /RELIABLE REGULATORY SUBMISSION
Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.
©2014 Factorytalk Co., Ltd. Proprietary and Confidential eCTD Specification 17 July 2014.
© 2008 Octagon Research Solutions, Inc. All Rights Reserved. 1 PhUSE 2010 Berlin * Accessing the metadata from the define.xml using XSLT transformations.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
Requirements for Standardized Study Data: Update on Guidance Ron Fitzmartin, PhD, MBA Data Standards Program Office of Strategic Programs Center for Drug.
Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
A web based Project Management and Tracking System Zheng Wang, Yuntian Zhao, Yanhong Li Biostatistics & Statistical programming.
DRAFT Guidance for Industry: Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing Denise Sánchez, J.D.,
EFPIA EFPIA IT Proposals ppt Slide 1 EFPIA Proposals for IT Support to the European Regulatory Procedures Mr S. Hasler EFPIA PAT Regulation 2000.
Regulatory Affairs Domain
Justina A. Molzon, MS Pharm, JD
Overview of FDA's Regulatory Framework for PET Drugs
Dr. Kurt Fendt, Comparative Media Studies, MIT MetaMedia An Open Platform for Media Annotation and Sharing Workshop "Online Archives:
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
1 XML as a preservation strategy Experiences with the DiVA document format Eva Müller, Uwe Klosa Electronic Publishing Centre Uppsala University Library,
1 World Intellectual Property Organization PCT-SAFE Preparing PCT Applications Electronically South Africa, February 5-9, 2007.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Tracking & Review Attaching Documents, Proposal Review, and Submission Office of Grant & Contract Services 17 January 2012.
DEPARTMENT OF HEALTH Medicines Regulatory Affairs
J. B. Chemicals & Pharmaceuticals Ltd. © Copyright 2005 J. B. Chemicals Pharma Ltd. Electronic Submissions – eCTD Advantages Dr Milind Joshi.
Regulated Product Submission HL7 Update Wednesday January 10 th, 2007 Jason Rock
Best Archival Practice in the Regulation of Medicines: Work on the Guidelines for Agencies for Medicinal Products Ph.D. Arian Rajh Agency for Medicinal.
Overview of FDA's Regulatory Framework for PET Drugs
The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Large Multicenter Clinical Trials George.
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
FDA ICH Public Meeting 5630 Fishers Lane, Rockville, MD May 8, :30 am -- 2:00 pm Implementation of the CTD Update-Issues-Next Steps Justina A. Molzon,
XBRL for regulatory reporting in Belgium Camille Dümm Central Balance Sheet Office (CBSO) Update on the CBSO latest developments and related projects.
SAPRAA 5 Sept 2008 eCTD An overview of the full day presentation by Dr Olaf Schoepke at the SAAPI conference in July 2008.
1 COMMON TECHNICAL DOCUMENT / ORIGIN OF CTD… ICH EWG CTD WAS OFFICIALLY SIGNED OFF IN NOVEMBER 2000, AT 5 TH ICH CONFERENCE; SAN DIEGO,CALIFORNIA.
BioUtah Pre-Submission Issues Workshop April 6, 2016 Ryan O’Callaghan Phil Triolo and Associates LC.
Accurate  Consistent  Compliant Contact: i4i the structured content company the structured content company.
DIA Electronic Submissions Meeting Olga Alfieri 26 April 2016
Swissmedic Swiss Agency for Therapeutic Products Hallerstrasse 7 CH-3000 Bern Swissmedic’s future steps 2nd Follow-up Information Meeting.
DMF Procedures and Communication between API, FFP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Swissmedic Swiss Agency for Therapeutic Products Hallerstrasse 7 CH-3000 Bern Workshop 2 - Paragraph 13 TPA 2nd Follow-up Information.
Abstract References Why CTD ? CTD is an ICH standard that FDA adopted in a consensus process, as a member of ICH, together with other member regions, Europe.
Online Information and Education Conference 2004, Bangkok Dr. Britta Woldering, German National Library Metadata development in The European Library.
© Copyright IBM 2007DIA ERS SIAC Presentation, January 2008 The HL7 RPS and SPL Standards - A High Level View Terry Hardin Sr. IT Architect Emerging Software.
Regulated Product Submission Eileen M. Girten, MS i3 Statprobe 1DIA Education SIAC.
DIA Trial Master File Reference Model
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
Regulatory Intelligence for the Emerging Markets Lisa Rysso-DeMaggio President, RAQUELIAN Consulting DIA Regulatory Intelligence Working Group, 10 Sep.
Validation Gary Gensinger Deputy Director Office of Business Process Support Center for Drug Evaluation and Research.
Open Access and Research Data Symplectic Pilot
Periodic Safety Update Reports (PSUR)
CTD Content Management
FDA Experience with eCTD
ACE Presentation for Industry
Nonclinical Information in the Common Technical Document: Opportunities for Content Reuse Peggy Zorn, MPI Research Susan Mattano, Pfizer, Inc.
eCTD Lifecycle Gary M Gensinger
Handling ongoing variations concerning same document
Welcome to: eCTD Hands-on Workshop
JSS College of Pharmacy Ooty, Tamil Nadu Sunday, April 24th , 2016
EU SUBMISSION BY Haripriya & Revathy.
Business Cases and Advantages of eCTD v4.0
Fundamentals of Electronic Submissions and eCTD
Business View on eCTD v4.0 Advantages and challenges when considering implementation to overcome constrains of the current eCTD specification.
SDTM and ADaM Implementation FAQ
WP 4 - Revision of Natura 2000 dataflow
An FDA Statistician’s Perspective on Standardized Data Sets
Presentation transcript:

CTD Dossier Preparation K. Srikantha Reddy Sr CTD Dossier Preparation K. Srikantha Reddy Sr.Manager-Regulatory Affairs Medreich Limited Srikanth.k@medreich.com

CTD Dossier Preparation CTD (Common Technical Document) contains 5 modules Module – 1 Module – 2 Module – 3 Module – 4 Module – 5

DMF Investigational New Drug Application (IND), Drug Master File (DMF) is a submission to the Food and Drug Administration (FDA) that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. The information contained in the DMF may be used to support following, Investigational New Drug Application (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA), Export Application.

ANDA: An Abbreviated New Drug Application (ANDA) is an application for a U.S. generic drug approval for an existing licensed medication or approved drug. The ANDA contains data which when submitted to FDA's Center For drug Evaluation and Research (CDER), Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low cost alternative to the American public.

Module – 1 (e.g. EU)

Module - 1

Module - 2

Module - 2

Module - 2

Module - 3

Module - 3

Module - 3

Module - 3

Module - 3

Module - 3

Module - 3

Module - 3

Module - 3

Module - 4

Module - 4

Module - 4

Module - 5

Module - 5

Module - 5

eCTD K. Srikantha Reddy Medreich Limited 06.05.2011 (Version 3.2.2) Sr. Manager-Regulatory Affairs Medreich Limited Srikanth.k@medreich.com

eCTD eCTD – electronic Common Technical Document The eCTD is the electronic equivalent to the CTD. Regulatory Perspective “The eCTD is defined as an interface for industry to agency transfer of regulatory information while at the same time taking into consideration the facilitation of the creation, review, lifecycle management and archival of the electronic submission.” Common structure for Modules 2 through 5 Agency specific requirements for Modules 1

eCTD Technical Perspective Structured set of common folders structure containing PDFs and SAS files (Statistical Analysis Software) on a CD/DVD (Can also be submitted through Agency web portals) The eCTD backbone is an XML file (Extensible Markup Language) representing the structure of the submission, it includes links to files and other metadata such as check sum information. The schema for the XML is very rigid. PDF hyperlinks

eCTD Granularity of files submitted is small (there are no longer issues of creating large volumes of PDFs). Increased potential for reusing the same submission content across agency submissions. The standard, and many of the modules have been agreed upon by the main worldwide agencies. Once a submission is sent in eCTD format all future submissions for the application should be in eCTD format. Opportunity to use Part 11 Compliant Electronic Signatures. Use only file formats specified in the guidance

eCTD Benefits Easy to distribute and review More efficient use of resources, less cost and stress to the organization Highly organized electronic table of contents Searchable Self-validating Integrated document and life-cycle management Cross submission integration Living document New, replace, append & delete

How it is different to Paper/Document CTD Overall Table of contents provided in XML (Extensible Markup Language) Utility files to enable technical conformance and viewing Submission Folders, XML and Utility Files are created automatically if an eCTD builder is used. Generally high level of granularity in documents Structure is more precise Lifecycle Management of the submission is easier.

eCTD Implementation - FDA Jan 1, 2008, eCTD became CDER’s standard for electronic submission. FDA has made it mandatory for all ELECTRONIC submissions to be in eCTD format since 2007-08. However, paper copies are still accepted. Suitable waivers will have to be taken before hand. The number of ANDA submissions to FDA has increased from 72 in the year 2006 to 1550 in 2009

eCTD Implementation - EU (http://esubmission.emea.europa.eu/) Requirements on Electronic submissions (Nees (Non-eCTD electronic submission, Version 2.0 March-2010) and eCTD) and paper documentation for New Application within MRP, DCP or National procedure – Refer CMDh/085/2008/Rev7 October 2010) From 1st July 2010, the EU M1 v1.4 must be used for all eCTD submissions for all European procedures,

eCTD Implementation - MHRA http://www. mhra. gov The preferred format for new marketing authorization (MA) applications is the electronic Common Technical Dossier (eCTD) eCTD applications must be created according to the current specifications: eCTD specification v 3.2.2 MHRA will accept applications in PDF-only format (Note that all PDF files included in an eCTD (irrespective of the module) should be v1.4, except where there is an agency‑specific requirement for a later version (e.g. for an application form)). The Summary of Product Characteristics (SmPC) will need to be prepared using the Word template. Use the MHRA Adobe Application form which is available via the MHRA Portal. This will produce an XML file that MHRA can upload directly into their database.

Regulatory Contact information

eCTD Modules When making an electronic submission, each document should be provided as a separate file. The documents, whether for a marketing application, an investigational application, or a related submission, should be organized based on the five modules in the CTD: Module 1 includes administrative information and prescribing information, Module 2 includes CTD summary documents, Module 3 includes information on quality, Module 4 includes the nonclinical study reports, and Module 5 includes the clinical study reports.

eCTD Template

eCTD Screen Shot

eCTD Screen Shot of Module 2

eCTD Screen Shot of Module 3

eCTD Screen Shot of Module 4

eCTD Screen Shot of Module 5

eCTD Screen Shot of Module 5

eCTD Screen Shot of Module 5

eCTD Management Software eCTDXPress – Image Solutions –http://www imagesolutions.com MasterControl Submissions Gateway™ - Master Control, http://www.mastercontrol.com Liquent’s EZsubs® software solution, http://www.liquent.com/ Data Farm, http://www.datafarminc.com/ Take solution : www.PharmaReady.com Lorenz Life Sciences : www.lorenz.cc

Thank You SRIKANTH.K